We used AS/siRNA to downregulate CTLA4 and observed up to 50% downregulation efficiency at the transcript and protein levels in low CD38-expressing CLL cells (Figure 1A–G). This evidence concerns the gene CTLA4 and B-cell chronic lymphocytic leukemia.